共 234 条
[1]
Eckel RH(2005)The metabolic syndrome Lancet 365 1415-1428
[2]
Grundy SM(2017)Metabolic syndrome prevalence by race/ethnicity and sex in the United States, National Health and Nutrition Examination Survey, 1988-2012 Prev. Chronic Dis. 14 E24-70
[3]
Zimmet PZ(2017)Cardiovascular consequences of metabolic syndrome Transl. Res. 183 57-467
[4]
Moore JX(2012)Integrated backscatter as a fibrosis marker in the metabolic syndrome: association with biochemical evidence of fibrosis and left ventricular dysfunction Eur. Heart J. Cardiovasc. Imaging 13 459-1012
[5]
Chaudhary N(2018)Metabolic syndrome is associated with impaired diastolic function independently of MRI-derived myocardial extracellular volume: the MESA study Diabetes 67 1007-403
[6]
Akinyemiju T(2002)Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N. Engl. J. Med. 346 393-877
[7]
Tune JD(2015)Novel therapeutic targets of metformin: metabolic syndrome and cardiovascular disease Expert Opin. Ther. Targets 19 869-62
[8]
Goodwill AG(2011)Metformin attenuates ventricular hypertrophy by activating the AMP-activated protein kinase-endothelial nitric oxide synthase pathway in rats Clin. Exp. Pharm. Physiol. 38 55-513
[9]
Sassoon DJ(2010)Metformin attenuates cardiac fibrosis by inhibiting the TGFbeta1-Smad3 signalling pathway Cardiovasc. Res. 87 504-196
[10]
Mather KJ(2014)METformin in diastolic dysfunction of MEtabolic syndrome (MET-DIME) trial: rationale and study design: MET-DIME trial Cardiovasc. Drugs Ther. 28 191-2752